Comorbidity in US patients with multiple sclerosis

Abstract

ObjectiveTo assess the trends in the prevalence of comorbidities in US patients with multiple sclerosis (MS), and the association of demographic characteristics with the presence of comorbidities.Study designA retrospective analysis was conducted from a sample of 5 million patients from the IMS Health Real World Data Adjudicated Claims – US database.MethodsComorbidity in patients with MS was assessed by year (2006–2014), and logistic regression models evaluated the association of age, sex, and region with select comorbidities.ResultsThe most common comorbidities from 2006 to 2014 were hyperlipidemia and hypertension (25.9%–29.7% of patients within an individual year), followed by gastrointestinal disease (18.4%–21.2% of patients) and thyroid disease (12.9%–17.1% of patients). The proportion with a claim for hyperlipidemia increased from 2006 to 2009, was stable from 2009 to 2011, and then declined from 2011 to 2014. The proportion with a claim for hypertension generally increased from 2006 to 2013, then declined from 2013 to 2014. The proportion with a claim for gastrointestinal disease, thyroid disease, and anxiety generally increased from 2006 to 2014. Claims for comorbidities were statistically significantly more likely among older age groups (p<0.05), with the exception of anxiety and alcohol abuse, which were statistically significantly less likely among older age groups. Claims for gastrointestinal disease (OR=0.75), thyroid disease (OR=0.36), chronic lung disease (OR=0.76), arthritis (OR=0.71), anxiety (OR=0.63), and depression (OR=0.69) were statistically significantly less likely among males versus females (all p<0.05). Claims for hyperlipidemia (OR=1.39), hypertension (OR=1.25), diabetes (OR=1.31), and alcohol abuse (OR=2.41) were significantly more likely among males (p<0.05). Many comorbidity claims were statistically significantly more likely in the Northeast and South compared with the Midwest and West.ConclusionThis study provides select comorbidity claims estimates in US patients with MS, and thus highlights the importance of comprehensive patient care approaches.

Nutrient Composition Comparison between the Low Saturated Fat Swank Diet for Multiple Sclerosis and Healthy U.S.-Style Eating Pattern

“…Hyperlipidemia and hypertension are two common comorbidities in pwMS [124]. Swank menu fat composition is consistent with dietary recommendations to reduce saturated fat and increase unsaturated fat [59,97], however, the level and types of unsaturated fat will vary with the quantity and types of oil consumed within the Swank diet guidelines.…”

Effects of Comorbid Fibromyalgia Syndrome on activities of daily living in multiple sclerosis patients

“…The fatigue incidence has been reported as 78 to 94%. However, no specific underlying mechanism has been revealed for fatigue seen in FMS or MS 26 . In a study on 207 MS patients, Kroencke et al assessed patients using the FSS and Self-Rating Depression scales.…”

Fatigue and Self-management among Multiple Sclerosis Patients

“…Moreover [57] stated that diabetes in multiple sclerosis contribute to the progression of MS and disability. [58,59] added that as MS progresses, patients encounter limitations; in their daily activities or working abilities. It can cause; extensive physical disabilities, delay MS diagnosis, increase hospitalization, increase the chance of death or lack of effective treatment and negative impact quality of life.…”